1. Medtech Insight
  2. >>Business
  3. >>Strategy

Stroke Devices: Innovation Drives Growth

Innovation is driving double-digit growth in the neurointerventional device market as an increasing number of medical device manufacturers develop newer, more effective devices for treating acute ischemic stroke. As new, stent-like retrieval systems and other next-generation neurothrombectomy devices hit the US market in the next few years, competition in this sector will also heat up as manufacturers try to differentiate their devices and jockey for a piece of the market, which is projected to reach almost $70 million by 2015.

Neurointerventional solutions for treating and preventing stroke continue to gain momentum, and several device-based treatments received a boost from new research presented at this year’s International Stroke Conference (ISC), held in New Orleans in February. Some of the most compelling data presented at ISC 2012 centered on the evolving field of neurothrombectomy devices, which are emerging as an exciting new therapeutic option for patients suffering from acute ischemic stroke (AIS). Such devices, which aim to quickly restore blood flow in cerebral arteries blocked by a clot, not only have the potential to greatly improve patient outcomes, but they may also expand the stroke treatment window well beyond what can be achieved with thrombolytic drugs alone.

It seems almost every medical device manufacturer in the neurovascular space is developing some variation of the “stentriever,” a next-generation mechanical thrombectomy device designed to quickly open blocked arteries in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.